Diagnostic Considerations

As previously mentioned, the ACR classification criteria require 4 of 11 specific findings, which have 96-99% specificity (see History). Differential diagnoses should include the following:

Infection
Malignancy
Toxic exposures
Other multisystem diseases

Specific conditions to consider in the differential diagnosis of systemic lupus erythematosus (SLE) include the following:

Acute anemia
Acute poststreptococcal glomerulonephritis
Chronic anemia
Angioedema
Anti-GBM antibody disease
Antiphospholipid antibody syndrome
Obsessive-compulsive disorder
Specific phobia
Trichotillomania
Appendicitis
Arthritis, conjunctivitis, urethritis syndrome
Septic arthritis
Autoimmune and chronic benign neutropenia
Autoimmune chronic active hepatitis
Dilated cardiomyopathy
Chronic granulomatous disease
Anorexia
Bacterial endocarditis
Bacterial pericarditis
Complement deficiency
Complement receptor deficiency
Evans syndrome
Fever without a focus
Fibromyalgia
Fulminant hepatic failure
Goodpasture syndrome
Graves disease
Congestive heart failure
Hematuria
Hemolytic-uremic syndrome
Henoch-Schönlein purpura
Mitral valve insufficiency
Mitral valve prolapse
Mixed connective tissue disease
Bipolar disorder
Depression
Dysthymic disorder
Hepatitis B
Hodgkin disease
Hyperthyroidism
Hypothyroidism
Kawasaki disease
Lymphadenopathy
Nephritis
Nephrotic syndrome
Nonviral myocarditis
Oliguria
Parvovirus B19 infection
Pleural effusion
Polyarteritis nodosa
Proteinuria
Rheumatic fever
Rheumatic heart disease
Serum sickness
Sjögren syndrome
Systemic sclerosis
Thyroid storm
Generalized anxiety
Behçet syndrome
Thyroiditis
Urticaria

Differential Diagnoses

Workup

Osler W. On the visceral manifestations of the erythema group of skin diseases. Am J Med Sci. 1904. 27:1.
Suzuki M, Ross GF, Wiers K, Nelson S, Bennett M, Passo MH, et al. Identification of a urinary proteomic signature for lupus nephritis in children. Pediatr Nephrol. 2007 Dec. 22(12):2047-57. [Medline].
Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. Journal of Experimental Medicine. 2005. 201:703-711. [Medline].
Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001 Nov 16. 294(5546):1540-3. [Medline].
Vallin H, Blomberg S, Alm GV, Cederblad B, Rönnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol. 1999 Jan. 115(1):196-202. [Medline]. [Full Text].
Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011 Mar 9. 3(73):73ra20. [Medline]. [Full Text].
Armstrong DL, Reiff A, Myones BL, Quismorio FP Jr, Klein-Gitelman M, McCurdy D. Identification of new SLE-associated genes with a two-step Bayesian study design. Genes Immun. 2009 May 14. [Medline].
Rodriguez-Pla A, Patel P, Maecker HT, Rossello-Urgell J, Baldwin N, Bennett L, et al. IFN priming is necessary but not sufficient to turn on a migratory dendritic cell program in lupus monocytes. J Immunol. 2014 Jun 15. 192 (12):5586-98. [Medline].
Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, Stolzenberg MC, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014 Dec. 124 (12):5516-20. [Medline]. [Full Text].
Rees F, Doherty M, Grainge MJ, Lanyon P, Davenport G, Zhang W. Mortality in systemic lupus erythematosus in the United Kingdom 1999-2012. Rheumatology (Oxford). 2016 May. 55 (5):854-60. [Medline].
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep. 40(9):1725. [Medline].
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug. 64(8):2677-86. [Medline]. [Full Text].
Male C, Foulon D, Hoogendoorn H, Vegh P, Silverman E, David M, et al. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood. 2005 Dec 15. 106(13):4152-8. [Medline].
Ross GS, Zelko F, Klein-Gitelman M, et al. A proposed framework to standardize the neurocognitive assessment of patients with pediatric systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010 Jul. 62(7):1029-33. [Medline]. [Full Text].
[Guideline] Brunner HI, Ruth NM, German A, Nelson S, Passo MH, Roebuck-Spencer T. Initial validation of the Pediatric Automated Neuropsychological Assessment Metrics for childhood-onset systemic lupus erythematosus. Arthritis Rheum. 2007 Oct 15. 57(7):1174-82. [Medline].
Brunner HI, Mina R, Pilkington C, et al. Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011 Sep. 63(9):1213-23. [Medline]. [Full Text].
Wenderfer SE, Lane JC, Shatat IF, von Scheven E, Ruth NM. Practice patterns and approach to kidney biopsy in lupus: a collaboration of the Midwest Pediatric Nephrology Consortium and the Childhood Arthritis and Rheumatology Research Alliance. Pediatr Rheumatol Online J. 2015 Jun 19. 13:26. [Medline]. [Full Text].
Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004 Feb. 65(2):521-30. [Medline].
Mina R, von Scheven E, Ardoin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012 Mar. 64(3):375-83. [Medline]. [Full Text].
Hajizadeh N, Laijani FJ, Moghtaderi M, Ataei N, Assadi F. A treatment algorithm for children with lupus nephritis to prevent developing renal failure. Int J Prev Med. 2014 Mar. 5 (3):250-5. [Medline]. [Full Text].
Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child. 2008 May. 93(5):401-6. [Medline].
Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Feb 26. 377(9767):721-31. [Medline].
Brunner HI, et al. Efficacy and safety of intravenous belimumab in children with systemic lupus erythematosus (PLUTO study, abstract 2867). Presented at 2018 ACR/ARHP Annual Meeting. October 23, 2018. Chicago, IL. [Full Text].
Groot N, de Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis. 2017 Dec. 76 (12):1965-1973. [Medline].
Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014 Jul 8. 83 (2):142-50. [Medline]. [Full Text].

Media Gallery

The classic malar rash, also known as a butterfly rash, with distribution over the cheeks and nasal bridge. Note that the fixed erythema, sometimes with mild induration as seen here, characteristically spares the nasolabial folds.
In systemic lupus erythematosus (SLE), many genetic-susceptibility factors, environmental triggers, antigen-antibody responses, B-cell and T-cell interactions, and immune clearance processes interact to generate and perpetuate autoimmunity.